Business
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
Approximately 15 million USDOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseasesOryzon will explore Aggression in specific subsets of Autism Spectrum Disorder (ASD) to expand the precision medicine clinical scope of vafidemstatOryzon will also explore the targeted activity of iadademstat in several difficult-to-treat neuroendocrine cancersFunding covers 64% of Oryzon’s VANDAM project total budgetFurther reinforces Oryzon’s robust financia
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Approximately 15 million USD","length":28,"tagName":"p"}]},{"val":[{"type":"text","content":"Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Oryzon will explore Aggression in specific subsets of Autism Spectrum Disorder (ASD) to expand the precision medicine clinical scope of vafidemstat","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Oryzon will also explore the targeted activity of iadademstat in several difficult-to-treat neuroendocrine cancers","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"Funding covers 64% of Oryzon’s VANDAM project total budget","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"Further reinforces Oryzon’s robust financial standing","length":53,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":510,"olType":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the publication of the Spanish provisional resolution proposal for Med4Cure, the first Important Project of Common European Interest (IPCEI) aimed to support research, innovation, and the first industrial deployment of pharmaceuticals and healthcare products in Europe, awarding Oryzon a non-refundable grant of 13,263,794 € (approximately 15 million USD) for its VANDAM project. This amount corresponds to 64% of the total accepted budget (20.68 million €) for the VANDAM Project.","length":694,"tagName":"p"},{"type":"text","content":"Dr. Carlos Buesa, CEO of Oryzon, stated: “This grant is a key pillar of Oryzon’s clinical strate...